Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant

P W Heald; E J Glusac

doi:10.1016/S0190-9622(00)90140-3

Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant

J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):283-5. doi: 10.1016/S0190-9622(00)90140-3.

Authors

P W Heald¹, E J Glusac

Affiliation

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.

PMID: 10642687
DOI: 10.1016/S0190-9622(00)90140-3

Abstract

Ten patients, mean age 61 years, who presented with unilesional cutaneous T-cell lymphoma (CTCL) were studied. Lesional structure and distribution were similar to disseminated CTCL. Ablative therapy was successful in all patients. The relatively benign behavior of unilesional CTCL may reflect the prognostic importance of minimal tumor burden. Locally ablative therapy in the management of localized CTCL appears effective.

MeSH terms

Administration, Topical
Adult
Aged
Antineoplastic Agents, Alkylating / therapeutic use
Carmustine / therapeutic use
Female
Humans
Lymphoma, T-Cell, Cutaneous* / drug therapy
Lymphoma, T-Cell, Cutaneous* / pathology
Male
Middle Aged
Mycosis Fungoides / drug therapy
Mycosis Fungoides / pathology*
Mycosis Fungoides / radiotherapy
Recurrence
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Carmustine